Comparative efficacy and safety of super-bioavailable itraconazole-130 mg once daily in obese and non-obese patients of glabrous tinea

Autor: Manjunath Shenoy, Abhishek De, Bela Shah, Anupam Das, Abir Saraswat, Koushik Lahiri, Dhiraj Dhoot
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Indian Dermatology Online Journal, Vol 14, Iss 6, Pp 839-843 (2023)
Druh dokumentu: article
ISSN: 2229-5178
DOI: 10.4103/idoj.idoj_120_23
Popis: Background: Obesity is considered one of the risk factors for dermatophytosis and warrants systemic therapy. Itraconazole is the most commonly used antifungal, but owing to pharmacokinetic challenges, super-bioavailable itraconazole (SITZ) was approved globally, recently. For the management of dermatophytosis in obese patients, there are mixed opinions regarding the dosing of systemic antifungals. Materials and Methods: This study was conducted to compare the efficacy and safety of SITZ-130 mg once daily in glabrous tinea or dermatophytosis in obese and non-obese patients for a total duration of 10 weeks on 87 eligible patients. Efficacy and safety assessments were done at weeks 3 and 6 with follow-up at week 10 for relapse. The primary objective was to assess the proportion of patients achieving complete cure at week 6 with the assessment of safety, clinical, and mycological cure rates as secondary objectives. Results: Out of 87 patients, 80 were considered for analysis. At week 6, 22/35 (63%) and 33/45 (73%) patients in obese and non-obese groups were completely cured (P = 0.47). Similarly, there was no statistically significant difference for mycological and clinical cure in both the groups (P = 0.17 and P = 0.61, respectively). Four patients in the obese group (18% of completely cured), while one patient in the non-obese group (3% of completely cured), relapsed within 4 weeks of completion of treatment (P = 0.14). The therapy was well tolerated by both groups, with only one patient in the non-obese group experiencing pruritus. Conclusion: SITZ-130 mg once daily achieved desired and similar clinical response in obese patients as of non-obese patients suffering from dermatophytosis, and hence, a higher dose may not require in obesity.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje